Journal of Inherited Metabolic Disease

, Volume 31, Issue 2, pp 205–216

Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review

  • M. F. B. Silva
  • C. C. P. Aires
  • P. B. M. Luis
  • J. P. N. Ruiter
  • L. IJlst
  • M. Duran
  • R. J. A. Wanders
  • I. Tavares de Almeida
SSIEM Symposium 2007

Summary

Valproic acid (VPA; 2-n-propylpentanoic acid) is widely used as a major drug in the treatment of epilepsy and in the control of several types of seizures. Being a simple fatty acid, VPA is a substrate for the fatty acid β-oxidation (FAO) pathway, which takes place primarily in mitochondria. The toxicity of valproate has long been considered to be due primarily to its interference with mitochondrial β-oxidation. The metabolism of the drug, its effects on enzymes of FAO and their cofactors such as CoA and/or carnitine will be reviewed. The cumulative consequences of VPA therapy in inborn errors of metabolism (IEMs) and the importance of recognizing an underlying IEM in cases of VPA-induced steatosis and acute liver toxicity are two different concepts that will be emphasized.

Abbreviations

CoA

coenzyme A

DILI

drug-induced liver injury

FAO

fatty acid β-oxidation

FFA

free fatty acids

IEM

inborn error of metabolism

RLM

rat liver mitochondria

VPA

valproic acid

References

  1. Abbott FS, Anari MR (1999) Chemistry and biotransformation. In: Löscher W, ed. Milestones in Drug Therapy-Valproate, Basel: Birkhäuser Verlag, 47–75.Google Scholar
  2. Abbott Laboratories (2007) Clinical Pharmacology of Divalproex, Abbott Laboratories Inc., USA: http://www.rxabbott.com/pdf/depakote.pdf.
  3. Aires CCP, Ruiter JPN, Luis PBM, et al (2007) Studies on the extra-mitochondrial CoA-ester formation of valproic and Δ4-valproic acids. Biochim Biophys Acta 1771: 533–543.PubMedGoogle Scholar
  4. Bailey MJ, Dickinson RG (1996) Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Chem Res Toxicol 9: 659–666.PubMedGoogle Scholar
  5. Baillie TA (1988) Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem Res Toxicol 1: 195–199.PubMedGoogle Scholar
  6. Baldwin GS, Abbott FS, Nau H (1996) Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation. FEBS Lett 8: 384, 1: 58–60.Google Scholar
  7. Battino D, Estienne M, Avanzini G (1995) Clinical pharmacokinetics of antiepileptic drugs in paediatric patients Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet 29: 257–286.PubMedGoogle Scholar
  8. Becker CM, Harris RA (1983) Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch Biochem Biophys 223: 381–392.PubMedGoogle Scholar
  9. Begriche K, Igoudjil A, Pessayre D, Fromenty B (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6: 1–28.PubMedGoogle Scholar
  10. Bjorge SM, Baillie TA (1991) Studies on the β-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab Dispos 19: 823–829.PubMedGoogle Scholar
  11. Bohan TP, Helton E, McDonald I, et al (2001) Effect of l-carnitine treatment for valproate-induced hepatotoxicity. Neurology 56: 1405–1409.PubMedGoogle Scholar
  12. Booth CL, Pollack GM, Brouwer KLR (1996) Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Hepatology 23: 771–780.PubMedGoogle Scholar
  13. Bryant AE, Dreifuss FE (1996) Valproic acid fatalities. III: US experience since 1986. Neurology 46: 465–469.PubMedGoogle Scholar
  14. Burchell B (1999) Transformation reactions: glucuronidation. In: Woolf TF, ed. Handbook of Drug Metabolism, New York: Marcel Dekker, 153–173.Google Scholar
  15. Burton BS (1882) On the propyl derivatives and decomposition products of ethylacetoacetate. Am Chem J 3: 385–395.Google Scholar
  16. Chabrol B, Mancini J, Chretien D, Rustin P, Munnich A, Pinsard N (1994) Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 153: 133–135.PubMedGoogle Scholar
  17. Chang TKH, Abbot FS (2006) Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab Rev 38: 627–639.PubMedGoogle Scholar
  18. Corkey BE, Hale DE, Glennon MC, et al (1988) Relationship between unusual hepatic acyl Coenzyme A profiles and the pathogenesis of Reye syndrome. J Clin Invest 82: 782–788.PubMedGoogle Scholar
  19. Cotariu D, Zaidman J (1988) Valproic acid and the liver. Clin Chem 34: 890–897.PubMedGoogle Scholar
  20. Davis R, Peters DH, McTavish D (1994) Valproic acid-a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47: 332–372.PubMedGoogle Scholar
  21. De Vivo DC, Bohan TP, Coulter DL, et al (1998) l-Carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 39: 1216–1225.PubMedGoogle Scholar
  22. Delarue A, Paut O, Guys JM, et al (2000) Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure. Pediatr Transplant 4: 67–71.PubMedGoogle Scholar
  23. DeVane CL (2003) Pharmacokinetics, drug interactions and tolerability of valproic acid. Psychopharmacol Bull 37(Supplement 2): 25–40.PubMedGoogle Scholar
  24. Dreifuss FE, Langer DH, Moline A, Maxwell E (1989) Valproic acid fatalities. II US experience since 1984. Neurology 39: 201–207.PubMedGoogle Scholar
  25. Dutta S, Zhang Y, Conway J, et al (2004) Divalproex ER-pharmacokinetics in older children and adolescents. Pediatr Neurol 30: 330–337.PubMedGoogle Scholar
  26. Evans AM, Fornasini G (2003) Pharmacokinetics of l-carnitine. Clin Pharmacokinet 42: 941–967.PubMedGoogle Scholar
  27. Farkas V, Bock I, Csako J, Sandor A (1996) Inhibition of carnitine biosynthesis by valproic acid in rats-the biochemical mechanism of inhibition. Biochem Pharmacol 52: 1429–1433.PubMedGoogle Scholar
  28. Fong JC, Schulz H (1978) On the rate-limiting step of fatty acid oxidation in heart: inhibition of fatty acid oxidation by 4-pentenoic acid. J Biol Chem 253: 6917–6922.PubMedGoogle Scholar
  29. Fromenty B, Pessayre D (1997) Impaired mitochondrial function in microvesicular steatosis: effects of drugs, ethanol, hormones and cytokines. J Hepatol 26(Supplement 2): 43–53.PubMedGoogle Scholar
  30. Gerber N, Dickinson RG, Harland RC, et al. (1979) Reye-like syndrome associated with valproic acid therapy. J Pediatr 95: 142–144.PubMedGoogle Scholar
  31. Gopaul SV, Farrell K, Abbott FS (2000) Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab Dispos 28: 823–832.PubMedGoogle Scholar
  32. Granneman GR, Wang S-I, Kesterson JW, Machinist JM (1984) Hepatotoxicity of valproic acid and its metabolites II Intermediary and valproic acid metabolism. Hepatology 4: 1153–1158.PubMedGoogle Scholar
  33. Gugler R, van Unruh GE (1980) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 5: 67–83.PubMedGoogle Scholar
  34. Hjelm M, Silva LVK, Seakins JWT, Oberholzer VG, Rolles CJ (1986) Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. Br Med J 292: 23–24.Google Scholar
  35. Holt MP and Ju C (2006) Mechanisms of drug-induced liver injury, AAPS J 8: 1, E48–E59.PubMedGoogle Scholar
  36. Ito M, Ikeda Y, Arnez JG, Finochiaro G, Tanaka K (1990) Theenzymatic basis for the metabolism and inhibitory effects ofvalproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. BiochimBiophys Acta 1034: 213–218.PubMedGoogle Scholar
  37. Jakobs C, Löscher W (1978) Identification of metabolites of valproic acid in serum of humans, dog, rat and mouse. Epilepsia 19: 591–602.PubMedGoogle Scholar
  38. Kassahun K, Farrell K, Abbott FS (1991) Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab Dispos 19: 525–535.PubMedGoogle Scholar
  39. Kassahun K, Hu P, Grillo P, Davis MR, Jin L, Baillie TA (1994) Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A—dependent and -independent processes. Chem-Biol Interact 90: 253–275.PubMedGoogle Scholar
  40. Katayama H, Watanabe M, Yoshitomi H, et al (1998) Urinary metabolites of valproic acid in epileptic patients. Biol Pharm Bull 21: 304–307.PubMedGoogle Scholar
  41. Kesterson JW, Granneman GR, Machinist JM (1984) The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4: 1143–1152.PubMedCrossRefGoogle Scholar
  42. Kibayashi M, Nagao M, Chiba S (1999) Influence of valproic acid on the expression of various acyl-CoA dehydrogenases in rats. Pediatr Int 41: 1:52–60.PubMedGoogle Scholar
  43. König SA, Siemes H, Bläker F, et al (1994) Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 35: 1005–1015.PubMedGoogle Scholar
  44. König SA, Schenk M, Sick C, et al (1999) Fatal liver failure associated with valproate therapy in a patient with Friedreich’s disease: a review of valproate hepatotoxicity in adults. Epilepsia 40: 1036–1040.PubMedGoogle Scholar
  45. Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lucking CH (2001) Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 11: 8, 757–759.PubMedGoogle Scholar
  46. Krähenbühl S, Brandner S, Kleinle S, Liechti S, Straumann D (2000) Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20: 4, 346–348.PubMedGoogle Scholar
  47. Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancies. Cancer 110: 943–954.PubMedGoogle Scholar
  48. Kuhara T, Hirohata Y, Yamada S, Matsumoto I (1978) Metabolism of sodium dipropylacetate in humans. Eur J Drug Metab Pharmacokinet 3: 171–177.Google Scholar
  49. Lam CW, Lou CH, Williams JC, Chan YW, Wong L (1997) Mitochondrial miopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 156: 562–564.PubMedGoogle Scholar
  50. Leão M (1995) Valproate as a cause of hyperammonemia in heterozygotes with ornitine-transcarbamylase deficiency. Neurology 45: 593–595.PubMedGoogle Scholar
  51. Lee M-H, HongI, Kim M, et al (2007) Gene expression profiles of murine fatty liver induced by the administration of valproic acid, Toxicol Appl Pharmacol 220: 45–59.PubMedGoogle Scholar
  52. Levy RH, Rettenmeier AW, Anderson GD, et al (1990) Effects of polytherapy with phenytoin, carbamazepine and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 48: 225–235.PubMedGoogle Scholar
  53. Lheureux PER, Penaloza A, Zahir S, Gris M (2005) Science review: carnitine in the treatment of valproic acid-induced toxicity—what is the evidence? Critical Care 9: 431–440.PubMedGoogle Scholar
  54. Li J, Norwood DL, Mao L-F, Schultz H (1991) Mitochondrial metabolism of valproic acid. Biochemistry 30: 388–394.PubMedGoogle Scholar
  55. Löscher W (1999) Pharmacological effects and mechanisms of action. In: Löscher W, ed. Milestones in Drug Therapy—Valproate, Basel: Birkhäuser Verlag 7–45.Google Scholar
  56. Löscher W (2002) Basic Pharmacology of valproate: a review ater 35 years of clinical use for the treatment of epilepsy, CNS Drugs, 16: 669–694.PubMedGoogle Scholar
  57. Löscher W, Böhme G, Schäfer H, Kochen W (1981) Effect of metabolites of valproic acid on the metabolism of GABA in brain and brain nerve endings. Neuropharmacology 20: 1187–1192.PubMedGoogle Scholar
  58. Matsumoto I, Kuhara T, Yoshino M (1976) Metabolism of branched medium chain length fatty acid II—β-oxidation of sodium dipropylacetate in rats. Biomed Mass Spectrom 3: 235–240.PubMedGoogle Scholar
  59. Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M (1963) Propriétés pharmacodynamiques de l’acide n-dipropylacétique. 1er Mémoire: propriétés antiépileptiques. Thérapie 18: 435–438.PubMedGoogle Scholar
  60. Millington DS, Bohan TP, Roe CR, Yergey AL, Liberato DJ (1985) Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta 145: 69–76.PubMedGoogle Scholar
  61. Moore KH, Decker BP, Schreefel FP (1988) Hepatic hydrolysis of octanoyl-CoA and valproyl-CoA in control and valproate-treated animals. Int J Biochem 20: 175–178.PubMedGoogle Scholar
  62. Mortensen PB, Gregersen N, Kølvraa S, Christensen E (1980) The occurrence of C6–C10 dicarboxylic acids in urine from patients and rats treated with dipropylacetate. Biochem Med 24: 153–161.PubMedGoogle Scholar
  63. Nau H, Löscher W (1982) Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and γ-aminobutyric acid (GABA) metabolism in the mouse. JPharmacol Exp Ther 220: 654–659.PubMedGoogle Scholar
  64. Nau H, Rating D, Koch S, Hauser I, Helge H (1981) Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 219: 768–777.PubMedGoogle Scholar
  65. Nau H, Löscher W, Löscher W (1984) Valproic acid and metabolites: pharmacological and toxicological studies. Epilepsia 25: 14–22.Google Scholar
  66. Oechsner M, Steen C, Sturenburg HJ, Kohlschutter A (1998) Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J Neurol Neurosur Psychiatr 64: 680–682.Google Scholar
  67. Ohashi R, Tamai I, Yabuuchi H, et al (1999) Na+-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291: 778–784.PubMedGoogle Scholar
  68. Owens MJ, Nemeroff CB (2003) Pharmacology of valproate. Psychopharmacol Bulletin 37(Supplement 2): 17–24.Google Scholar
  69. Papadimitriou A, Servidei S (1991) Late onset lipid storage myopathy due to multiple acyl-CoA dehydrogenase deficiency triggered by valproate. Neuromuscular Disord 1: 247–252.Google Scholar
  70. Perucca E (2002) Pharmacological and therapeutic properties of valproate. CNS Drugs 16: 695–714.PubMedGoogle Scholar
  71. Pessayre D, Mansouri A, Haouzi D, Fromenty B (1999) Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 15: 367–373.PubMedGoogle Scholar
  72. Ponchault S, van Hoof F, Veitch K (1992) In vitro effects of valproate and valproate metabolites on mitochondrial oxidations: relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 43: 11 2435–2442.Google Scholar
  73. Porter RJ, Meldrum BS (2001) Antiseizure drugs. In: Katzung BG, ed. Basic & Clinical Pharmacology. Lange Medical Books/McGraw-Hill, 395–418.Google Scholar
  74. Radatz M, Nau H (1999) Toxicity. In: Löscher W, ed. Milestones in Drug Therapy—Valproate, Basel: Birkhäuser Verlag, 91–128.Google Scholar
  75. Raskind JY, El-Chaar GM (2000) The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother, 34: 630–638.PubMedGoogle Scholar
  76. Rettenmeier AW, Prickett KS, Gordon WP, et al (1985) Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab Dispos 13: 81–96.PubMedGoogle Scholar
  77. Rettenmeier AW, Gordon WP, Prickett KS, Levy RH, Baillie TA (1986) Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Drug Metab Dispos 14: 454–464.PubMedGoogle Scholar
  78. Rettenmeier AW, Gordon WP, Barnes H, Baillie TA (1987) Studies on the metabolic fate of valproic acid in the ratusing stable isotope techniques. Xenobiotica 17: 1147–1157.PubMedGoogle Scholar
  79. Rettie AE, Rettenmeier AW, Howald WN, Baillie TA (1987) Cytochrome P450-catalysed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science 235: 890–893.PubMedGoogle Scholar
  80. Russell S (2007) Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr 19: 206–210.PubMedGoogle Scholar
  81. Sadeque AJM, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 283: 698–703.PubMedGoogle Scholar
  82. Scheffner D, König SA, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach St (1988) Fatal liver failure in 16 children with valproate therapy. Epilepsia 29: 530–542.PubMedGoogle Scholar
  83. Schmidt D (1999) Adverse effects and interactions with other drugs. In: Löscher W, ed. Milestones in Drug Therapy—Valproate, Basel: Birkhäuser Verlag, 223–264.Google Scholar
  84. Sewell AC, Bohles HJ, Herwig J, Demirkol M (1995) Neurological deterioration in patients with urea cycle disorders under valproate therapy-a cause for concern. Eur J Pediatr 154: 593–594.PubMedGoogle Scholar
  85. Shenn DD (1999) Absorption, distribution and excretion. In: Löscher W, ed. Milestones in Drug Therapy—Valproate, Basel: Birkhäuser Verlag 77–90.Google Scholar
  86. Shirley MA, Hu P, Baillie TA (1993) Stereochemical studies on the β-oxidation of valproic acid in isolated rat hepatocytes. Drug Metab Dispos 21: 580–586.PubMedGoogle Scholar
  87. Shorvon SD (1990) Epidemiology, classification, natural history and genetics of epilepsy. Lancet 336: 93–96.PubMedGoogle Scholar
  88. Silva MFB, Ruiter JPN, IJlst L, et al (2001a) Synthesis and intramitochondrial levels of valproyl-CoA metabolites. Anal Biochem 290: 60–67.Google Scholar
  89. Silva MFB, Ruiter JPN, IJlst L, et al (2001b) Differential effect of valproate and its Δ2- and Δ4-unsaturated metabolites, on the β-oxidation rate of long-chain and medium-chain fatty acids. Chem-Biol Interact 137: 203–212.Google Scholar
  90. Silva MFB, Selhorst J, Overmars H, et al (2001c) Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS. Clin Biochem 34: 635–638.Google Scholar
  91. Silva MFB, Ruiter JPN, Overmars H, et al (2002) Complete β-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 362: 755–760.PubMedGoogle Scholar
  92. Silva MFB, IJlst L, Allers P, et al (2004) Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria. Drug Metab Dispos 32(11): 1304–1310.PubMedGoogle Scholar
  93. Spahn-Langguth H, Benet LZ (1992) Acylglucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24, 5–47.PubMedGoogle Scholar
  94. Sztajnkrycer MD (2002) Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40: 789–801.PubMedGoogle Scholar
  95. Tein I, Xie ZW (1994) Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. Biochem Biophys Res Commun 204: 753–758.PubMedGoogle Scholar
  96. Thurston JH, Carroll JE, Dodson WE, Hauhart RE, Tash V (1983) Chronic valproate administration reduces fasting ketonemia in children. Neurology 33: 1348–1350.PubMedGoogle Scholar
  97. Tong V, Teng XW, Chang TKH, Abbot FS (2005) Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity and valproic acid metabolite levels in rats. Toxicol Sci 86: 427–435.PubMedGoogle Scholar
  98. Turnbull DM, Bone AJ, Bartlett K, Koundakjian PP, Sherratt HAS (1983) The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. Biochem Pharmacol 32: 1887–1892.PubMedGoogle Scholar
  99. Vajda FJ, Donnan GA, Phillips J, Bladin PF (1981) Human brain, plasma and cerebrospinal fluid concentration of sodium valproate after 72 h of therapy. Neurology 31: 486–487.PubMedGoogle Scholar
  100. Verrotti A, Trotta D, Morgese G, Chiarelli F (2002) Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 17: 367–373.PubMedGoogle Scholar
  101. Wagner CA, Lukewille U, Kaltenbach S, et al (2000) Functional and pharmacological characterization of human Na+-carnitine cotransporter hOCTN2. Am J Physiol Renal Physiol 279: F584–591.PubMedGoogle Scholar
  102. Watkins PB, Seeff LB (2006) Drug-induced liver injury: summary of a single topic clinical research conference, Hepatology 43: 3, 618–631.PubMedGoogle Scholar
  103. Werner T, Treiss I, Kohlmueller D, et al (2007) Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. Epilepsia 48: 72–76.PubMedGoogle Scholar
  104. Williams AM, Worrall S, de Jersey J, Dickinson RG (1992) Studies on the reactivity of acylglucuronides – III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans. Biochem Pharmacol 43: 745–755.PubMedGoogle Scholar
  105. Wu SP, Shyu MK, Liou HH, Gau CS, Lin CJ (2004) Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia 43: 204–210.Google Scholar
  106. Yao K-W, Mao L-F, Luo MJ, Schulz H (1994) The relationship between mitochondrial activation and toxicity of some substituted carboxylic acids. Chem-Biol Interact 90: 225–234.PubMedGoogle Scholar
  107. Zaccara G, Messori A, Moroni F (1988) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 15: 367–389.PubMedGoogle Scholar
  108. Zimmerman HJ, Ishak HJ (1982) Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 2: 591–597.PubMedCrossRefGoogle Scholar
  109. Zschocke J, Ruiter JP, Brand J, et al (2000) Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism. Pediatr Res 48: 852–855.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • M. F. B. Silva
    • 1
  • C. C. P. Aires
    • 1
  • P. B. M. Luis
    • 1
  • J. P. N. Ruiter
    • 1
  • L. IJlst
    • 1
  • M. Duran
    • 2
  • R. J. A. Wanders
    • 2
  • I. Tavares de Almeida
    • 2
  1. 1.Centro de Patogénese Molecular-UBMBE, iMed.ULFaculdade de Farmácia da Universidade de LisboaLisboaPortugal
  2. 2.Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry and Pediatrics, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations